Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Bioadaptives (BDPT) Operating Income (2019 - 2025)

Bioadaptives' Operating Income history spans 7 years, with the latest figure at -$248117.0 for Q4 2025.

  • Quarterly results put Operating Income at -$248117.0 for Q4 2025, up 26.45% from a year ago — trailing twelve months through Dec 2025 was -$1.0 million (down 73.09% YoY), and the annual figure for FY2025 was -$1.0 million, down 73.09%.
  • Operating Income for Q4 2025 was -$248117.0 at Bioadaptives, up from -$265689.0 in the prior quarter.
  • In the past five years, Operating Income ranged from a high of -$18975.0 in Q1 2023 to a low of -$337339.0 in Q4 2024.
  • The 5-year median for Operating Income is -$132619.0 (2022), against an average of -$146558.2.
  • The sharpest move saw Operating Income tumbled 897.05% in 2021, then skyrocketed 89.11% in 2023.
  • Year by year, Operating Income stood at -$177734.0 in 2021, then skyrocketed by 84.64% to -$27302.0 in 2022, then tumbled by 126.3% to -$61784.0 in 2023, then tumbled by 446.0% to -$337339.0 in 2024, then grew by 26.45% to -$248117.0 in 2025.
  • According to Business Quant data, Operating Income over the past three periods came in at -$248117.0, -$265689.0, and -$279219.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.